Monday 3 March 2014

Welcome, and a beginner's guide to DMD

Welcome to Diary of a Duchenne Mum!

I could plunge in the deep end, and tell you about the multiple things I'm dealing with today:  chasing up the neuromuscular consultant to rebook an appointment for T; replying to the contractor who has just sent us an estimate for making adaptations to our kitchen to make it wheelchair accessible; preparing for the meeting with T's special school tomorrow; negotiating with T on whether he wears pants today....  These are all posts in their own right, and I'll get to them all in turn in the next days and weeks.

But first, to introduce us:  I'm in my late forties and live in the UK with my husband B and our ten year old son.  Let's call him Tom.  I'm keeping the blog anonymous, partly to protect our son, but also because I want to be able to be completely honest and tell it like I experience it.  Tom was diagnosed with Duchenne muscular dystrophy five and a half years ago, when he was four and a half.  We have been on a Duchenne journey ever since.  Of course, having Duchenne is just one thing about Tom.  He's also a sparky, imaginative, sociable, loving kid who's got loads of ideas and interest in the world, and is out there living life to the full.

Over the years of the Duchenne journey so far, I've written a number of things about Duchenne for a wider audience.  To kick off this blog, here is the one that sets the scene of what Duchenne muscular dystrophy is:  a beginner's guide to Duchenne, its causes and potential treatments.    




Duchenne Muscular Dystrophy: 
a beginner’s guide to its cause and potential treatments


What is Duchenne muscular dystrophy?
Duchenne muscular dystrophy (DMD) is a progressive muscle wasting condition.  It is relatively rare - roughly one in seven thousand births – and affects mainly boys. 

People with DMD gradually lose strength in the skeletal muscles.  Later the heart and respiratory muscles are involved.  DMD does not affect continence, speech, or eye movements. 

On average boys with DMD begin to need a wheelchair full time between the ages of eight and twelve.

Life expectancy when DMD is untreated is around nineteen years.  With specialist care management life expectancy can rise into the thirties and even forties.  Work being done on potential new treatments gives realistic hope of even longer lives for the current generation of boys growing up with DMD – the hope that DMD might become a long-term manageable condition.

What causes Duchenne muscular dystrophy?
Lack of a crucial protein called dystrophin:
To work, our muscle cells need a protein called dystrophin.  Dystrophin is crucial for holding muscle cell walls together.  It is like scaffolding for the cell wall.  It holds in place a number of other proteins which all help the cell wall work properly.  Dystrophin is also like a shock absorber.  It is springy.  This enables muscle cells to absorb impact without getting damaged.

People with DMD do not have any dystrophin in their muscle cells.

Why do people with DMD lack dystrophin?
In every cell of the body there is an instruction book called DNA.  It is made up of chemicals and those chemicals act just like letters and words.  DNA contains instructions for the body to make everything it needs to grow and to maintain itself, including dystrophin and thousands of other proteins.

DNA has twenty two chapters plus a chapter called X.  The scientific name for these chapters is chromosomes.  In chapter X there is a paragraph giving the instruction for dystrophin.

Imagine that you are in a muscle cell.  In this imaginary cell you are going to use the DNA instruction to make dystrophin out of Lego bricks.  You turn to the paragraph in Chapter X and you read this instruction:

            Start with blue brick then green brick then blue brick then
red brick yellow brick red brick yellow brick red brick yellow brick
red brick yellow brick red brick yellow brick red brick yellow brick
red brick yellow brick red brick yellow brick red brick yellow brick
blue brick green brick blue brick.

Fine:  you make dystrophin.  But imagine that you turn to the dystrophin paragraph and instead get this instruction:

            Start with blue brick then green brick then blue brick then
            rbr ickye llowbr ickre dbr ickye llowbr ickre dbr ickye llowbr ickre
dbr ickye llowbr ickre dbr ickye llowbr ickre dbr ickye llowbr ickre
dbr  ickye llowbr ickre dbr ickye llowbr ickre dbr ickye llowbr ickbl
uebr ickgr eenbr ickbl uebr ick.

The instruction is unreadable.  You can’t make dystrophin.  Two letters have been missed out.  The words are all of the right length.  The other letters have shunted up, in the place of the missing letters.  The result is gobbledegook.

Now imagine that you turn to the dystrophin paragraph and instead of the previous examples you get this instruction:

            Start with blue brick then green brick then blue brick then
            red.

There is a full stop before the instruction has finished.  You can’t make dystrophin.

If the body can’t make dystrophin, the muscle cell dies.  The long term effect of this is that muscle fibre degenerates and is replaced by fatty tissue.

 What I have outlined here are the two kinds of mistake that can occur in DNA instructions.  In about 85 – 90% of DNA mistakes, letters are missed out or added.  In about 10 – 15% of mistakes, full stops are put in before the end of the instruction.  When these mistakes happen, the body can’t follow the instruction and can’t make the protein.

These two kinds of mistake can happen anywhere in the DNA instruction book.  Depending on where they are they cause different conditions.  Haemophilia, cystic fibrosis, some forms of sight loss, and predisposition to certain cancers are all examples of conditions caused by DNA mistakes.

The body does have a back-up plan.  Girls get a full copy of the twenty-two chapters plus chapter X.  Every cell contains two full copies of DNA.  If there is a mistake on one copy, the body can use the other copy.  Boys get a copy of the twenty-two chapters, but instead of a second chapter X they get chapter Y.  Chapter Y contains instructions for making testicles, but it doesn’t contain the instructions that are in chapter X for making dystrophin and some other crucial proteins.  That is why it is usually only boys who get Duchenne muscular dystrophy. 

How are scientists tackling Duchenne muscular dystrophy?
Scientists are exploring a number of ways to tackle Duchenne muscular dystrophy and turn it into a manageable condition.  The main approaches are listed below.  Different research projects are at different stages of development.  We are looking at a time scale of five to ten years for research to produce the first treatments.

Target the DNA mistake
Exon skipping targets DNA instructions which have been turned into gobbledegook.  It cuts letters out of the faulty instruction so that the letters get back in the right place.  In the example here, you could cut the underlined letters to restore a readable instruction:

Start with blue brick then green brick then blue brick then
            rbr ickye llowbr ickre dbr ickye llowbr ickre dbr ickye llowbr ickre
dbr ickye llowbr ickre dbr ickye llowbr ickre dbr ickye llowbr ickre
dbr  ickye llowbr ickre dbr ickye llowbr ickre dbr ickye llowbr ickbl
uebr ickgr eenbr ickbl uebr ick.

You would not get full dystrophin but it would work.  Duchenne muscular dystrophy would become a milder condition called Becker muscular dystrophy:  still muscle degeneration, but usually much less severe and life-shortening than DMD.  A number of scientists are working on exon skipping, including Matthew Wood at Oxford University in the UK and Steve Wilton in Perth, Western Australia.

Ataluren is a drug which targets premature full stops.  It aims to enable the body to ‘read through’ the premature full stop.  In cases of premature full stops, the rest of the instruction is there, but the body does not read it because it stops at the full stop.  Ataluren could potentially restore full-length dystrophin.  It is being trialled by an American pharmaceutical company called PTC Therapeutics.

Bring in dystrophin from outside the body
Adeno-associated virus vectors (AAV):  this approach uses empty virus ‘shells’ to bring dystrophin into the body and transport it to every cell.  There are two main difficulties which need to be overcome here.  The first is that dystrophin is very big, as you would expect of a protein which is a cell wall scaffolding and shock absorber – too big to fit into viruses without being modified.  The second is the problem of immune responses by the body to incoming viruses.  AAV is being explored by Keith Foster at Reading University in the UK.

Replace dystrophin with another protein
Utrophin is a protein which does the same job as dystrophin at the foetal stage and shortly after birth.  It is then switched off.  Kaye Davies and her team at Oxford University are working to develop a drug which would keep utrophin switched on and boosted up to replace dystrophin.

Build up muscle to compensate
Steroids are currently used to help prolong muscle strength.  While they do have some effect, they can’t boost up muscle strength to anywhere near the level needed and they have a lot of side effects.

Myostatin inhibitors:  myostatin is a substance in the body which stops it from making too much muscle.  If myostatin could be switched off or inhibited, the body would make more muscle, potentially enough to compensate for the continuous muscle loss in DMD.  George Dickson at Royal Holloway College, University of London, is working on this approach.

Stem cells:  these are cells in the body with the potential to turn into any kind of cell.  It might be possible to direct stem cells to turn into muscle cells.  Research into stem cell use for Duchenne muscular dystrophy is being done by Jenny Morgan at University College, University of London.


No comments:

Post a Comment